Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03515096|
Recruitment Status : Recruiting
First Posted : May 3, 2018
Last Update Posted : July 22, 2020
|Condition or disease||Intervention/treatment||Phase|
|Eltrombopag Hematopoietic Stem Cell Transplantation Thrombocytopenia||Drug: Eltrombopag Drug: rhTPO||Phase 3|
Hematopoietic stem cell transplantation (HSCT) is an important method to treat malignant tumor of blood system, and promoting platelets after HSCT is one of the important factors to determine the success of transplantation.
Recently, the main effective method to treat thrombocytopenia after transplantation is to preventively transfuse platelets. However, this method can cause platelet transfusion related graft-versus-host disease(GVHD), increase the risk of reaction and infection associated with blood transfusion, easily produce platelet related and specific antibodies (HPA), which seriously affect the curative effect of platelet infusion and even render platelet transfusion invalid. Besides, study has shown that the effective rate of platelet transfusion is 30%-70%, and the application of platelets in clinic is limited because of the shortage of blood supply at present.
Recombinant human thrombopoietin (rhTPO) is a glycoprotein molecule modified by full-length glycosylation and is of a similar pharmacological effect with endogenous thrombopoietin (TPO). TPO is a specific cytokine of megakaryocyte, which can promote the proliferation and maturation of macronuclear progenitor cells by binding to the receptor c-mpl. In addition, the chinese State Food and Drug Administration (SFDA) approved rhTPO for the treatment of thrombocytopenia after tumor chemotherapy in 2006. The study shows that rhTPO can increase the mean value of platelet count in the low period of platelet, shorten the time of low platelet, and improve the peripheral blood platelet aggregation rate in the bone marrow depression period.
Eltrombopag is the first oral non-peptide receptor (TPO-R) agonist, which can induce the proliferation and maturation of macronuclear progenitor cells via the Janus kinase (JAK) /signal transducer and activator of transcription (STAT) pathway. In 2008, the U.S. FDA approved the use of eltrombopag for the treatment of chronic idiopathic thrombocytopenia, and it has been widely used in tumor patients with thrombocytopenia after chemotherapy. Tanaka et al. have proved that eltrombopag can improve the average elevation of the platelet count in the bone marrow depression period in patients with stem cell transplantation. Besides, within the 9 patients receiving transplantation, the complete response of patients with primary and secondary thrombocytopenia were 60% and 71% respectively.
In China, studies showed that rhTPO could promote the recovery of platelet count, effectively reduce the infusion of platelet, decrease the risk of transplanting hemorrhage in acute leukemia patients after allo-HSCT. However, it is not clear that the effect of eltrombopag on improving platelet count after the treatment of HSCT. In addition, the comparison of efficacy and safety of eltrombopag vs rhTPO on platelet recovery after HSCT in clinical trial is not investigated. Therefore, it is of great significance to explore the efficacy and safety of eltrombopag and rhTPO in improving the recovery of platelet count after HSCT, which will provide a better method to recover platelet after HSCT.
The purpose of this study is to compare the efficacy of Eltrombopag vs rhTPO in complete response in patients after HSCT in China. To be more precise, Eltrombopag is taken 50 mg po daily from day 1 until platelet is completely effectively recovered after HSCT, while rhTPO is given by subcutaneous injection 15000 u daily from day 1 until platelet is completely effectively recovered after HSCT.
Complete response (CR) is defined as a platelet count more than 50×109/L without injection of platelet for 7 days. Partial response (PR) is defined as a platelet count more than 30×109/L without injection of platelet for 7 days.
After 21 days' treatment, a follow-up of all patients will be performed every week in the following 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||156 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Eltrombopag vs. Recombinant Human Thrombopoietin to Increase Platelet Level After Hematopoietic Stem Cell Transplantation: an Equivalent, Open-label, Randomized-controlled Study|
|Actual Study Start Date :||July 1, 2018|
|Estimated Primary Completion Date :||December 2, 2020|
|Estimated Study Completion Date :||June 1, 2021|
Thrombopoietin- receptor (TPO-R) agonist
Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
Placebo Comparator: rhTPO
Recombinant human thrombopoietin (rhTPO)
rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
Other Name: no other name
- Number of Participants (Responders) Achieving a Platelet Count >=50×10^9/L On Day 21 After HSCT [ Time Frame: From the start of study treatment (Day 1) to days 21 ]On days 21 after HSCT, the number of participants (responders) with platelet count >=50x10^9/L and no platelet infusion for 7 days were compared between treatments
- Number of Participants (Responders) Achieving a Platelet Count >=30×10^9/L On Day 21 After HSCT [ Time Frame: From the start of study treatment (Day 1) to days 21 ]On days 21 after HSCT, the number of participants (responders) with platelet count >=30x10^9/L and no platelet infusion for 7 days were compared between treatments
- Number of Participants (Responders) Achieving a Platelet Count >=100×10^9/L On Day 21 After HSCT [ Time Frame: From the start of study treatment (Day 1) to days 21 ]On days 21 after HSCT, the number of participants (responders) with platelet count >=100x10^9/L and no platelet infusion for 7 days were compared between treatments
- Number of Participants With Bleeding events as Assessed Using the predefined bleeding scoring system. [ Time Frame: From the start of study treatment (Day 1) to days 90 ]The predefined bleeding scoring system is a measure of bleeding severity with the following score: score 0 = no bleeding, score 1= occult blood in body secretions (detected by heme-positive dipstick), mild petechiae, or minimal vaginal spotting, score 2= minor bleeding that does not require red blood cells (RBC) transfusions over routine transfusion needs (epistaxis, vaginal bleeding, mild hematemesis, melena, and mild hematuria) 3 = hemorrhage causing rapid decrease in hematocrit level, necessitating one or more units of RBCs per day beyond routine transfusion needs, and score 4 = Life-threatening hemorrhage, defined as either massive bleeding causing severe hemodynamic compromise or bleeding into vital organ (e.g., intracranial hemorrhage, pericardial, or diffuse alveolar hemorrhage).
- Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) [ Time Frame: From the start of study treatment (Day 1) to days 90 ]An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, is a congenital anomaly/birth defect or is associated with protocol specified liver injury and impaired liver function or is any protocol specific AEs.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03515096
|Contact: XIN DU, MD||075583366388 ext email@example.com|
|Shenzhen Second People's Hospital||Recruiting|
|Shenzhen, Guangdong, China, 518035|
|Contact: Xin Du, MD 075583366388 ext 8196 firstname.lastname@example.org|
|Principal Investigator:||XIN DU, MD||Second People's Hospital of Shenzhen|